Contents lists available at AcademiansEdu

International Journal of Clinical and Biomedical Sciences

journal homepage:

Research Article

SARS-CoV-2 Infection and Adrenal Dysfunction: A Comprehensive Review of Cortisol Secretion, Glucocorticoid Receptor Signaling, and Hypothalamic-Pituitary-Adrenal Axis Dysregulation

Teodora I

Independent Scholar

ARTICLE INFO

Keywords: COVID-19, SARS-CoV-2, Adrenal Gland, Cortisol, HPA Axis, Glucocorticoid Receptor, Adrenal Insufficiency, CIRCI, Cytokine Storm.

ABSTRACT

COVID-19, caused by SARS-CoV-2, affects multiple organ systems beyond the lungs, including the endocrine system. Recent studies suggest that the adrenal glands and the hypothalamic–pituitary–adrenal (HPA) axis may be disrupted during infection, leading to altered cortisol regulation. This review examines the mechanisms through which SARS-CoV-2 influences adrenal function and cortisol secretion.

A systematic literature review was conducted using PubMed, Scopus, Web of Science, and Embase databases for studies published between 2020 and 2024. The review focused on research addressing adrenal gland involvement, cortisol regulation, glucocorticoid receptor function, and HPA axis alterations in COVID-19 patients.

Evidence indicates that SARS-CoV-2 may directly affect adrenal tissue through ACE2 and TMPRSS2 receptors. Adrenal dysfunction may occur through several mechanisms, including viral cytopathic effects, inflammation during cytokine storm, molecular mimicry affecting ACTH, and glucocorticoid receptor resistance. These processes can lead to conditions such as adrenal insufficiency and critical illness-related corticosteroid insufficiency (CIRCI). Some recovered patients also show temporary hypocortisolism due to central HPA axis disruption.

Overall, SARS-CoV-2 infection can significantly influence cortisol regulation and adrenal function. Awareness of these endocrine complications is important for clinical management and long-term monitoring of post-COVID-19 patients.

1. INTRODUCTION

1.1 The Endocrine Impact of SARS-CoV-2: An Emerging Paradigm

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has fundamentally reshaped global health priorities and scientific inquiry since its emergence in late 2019. While the respiratory manifestations of this viral infection initially dominated clinical attention, the subsequent recognition of widespread extrapulmonary involvement has fundamentally altered our understanding of SARS-CoV-2 pathophysiology (Gupta et al., 2020). Among the diverse organ systems affected, the endocrine system—and particularly the adrenal glands—has emerged as a significant and clinically relevant target of viral-induced dysfunction (Oguz & Yildiz, 2023).

Coronaviruses constitute a large family of enveloped, positive-sense RNA viruses capable of infecting diverse mammalian and avian species. Prior to the COVID-19 pandemic, two highly pathogenic coronaviruses had been identified: severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), which emerged in 2002-2003, and Middle East respiratory syndrome coronavirus (MERS-CoV), first identified in 2012 (de Wit et al., 2016). Each of these predecessors demonstrated capacity for extrapulmonary dissemination, including endocrine tissue involvement, though the scale of the COVID-19 pandemic has provided unprecedented opportunity to study viral-endocrine interactions across diverse populations and disease severities.

1.2 The Hypothalamic-Pituitary-Adrenal Axis: Physiological Overview

The hypothalamic-pituitary-adrenal (HPA) axis represents a fundamental neuroendocrine system mediating the organism's response to stress, maintaining metabolic homeostasis, and regulating immune function (Smith & Vale, 2022). This hierarchical system operates through integrated feedback loops: corticotropin-releasing hormone (CRH) synthesized in the

https://doi.org/

Received 20 December 2025; Received in revised form 18 January 2026; Accepted 30 January 2026

Available online 26 February 2026

paraventricular nucleus of the hypothalamus stimulates pituitary corticotroph cells to secrete adrenocorticotropic hormone (ACTH), which in turn drives adrenal cortisol production and release.

Cortisol, the principal glucocorticoid hormone in humans, exerts pleiotropic effects essential for survival under stress conditions. These include:

- **Metabolic actions**: Stimulation of gluconeogenesis, glycogenolysis, and lipolysis; inhibition of glucose uptake in peripheral tissues; and protein catabolism in muscle
- **Cardiovascular effects**: Maintenance of vascular tone, endothelial integrity, and cardiac contractility; potentiation of catecholamine actions
- **Immunomodulatory functions**: Suppression of proinflammatory cytokine production; inhibition of nuclear factor kappa-B (NF-κB) signaling; promotion of lymphocyte apoptosis; and regulation of T-helper cell differentiation
- **Central nervous system effects**: Modulation of mood, cognition, and behavior; feedback inhibition of CRH and ACTH secretion

The adrenal cortex comprises three histologically and functionally distinct zones: the zona glomerulosa (mineralocorticoid production), zona fasciculata (glucocorticoid production), and zona reticularis (adrenal androgen production). Cortisol synthesis occurs primarily in the zona fasciculata through a series of enzymatic reactions converting cholesterol to pregnenolone and subsequently to cortisol via 11β-hydroxylase (CYP11B1) activity (Miller & Auchus, 2019).

1.3 SARS-CoV-2 Entry Mechanisms and Endocrine Tropism

The initial step in SARS-CoV-2 infection involves viral spike (S) protein binding to the host cell membrane receptor, angiotensin-converting enzyme 2 (ACE2) (Hoffmann et al., 2020). This interaction is facilitated by transmembrane serine protease 2 (TMPRSS2), which cleaves the spike protein to expose fusion peptides enabling viral entry. The tissue distribution of ACE2 and TMPRSS2 expression largely determines the organotropism of SARS-CoV-2.

Multiple studies have demonstrated significant ACE2 and TMPRSS2 expression in endocrine tissues, including:

- **Adrenal glands**: Expression localized predominantly to the adrenal cortex, with highest levels in zona fasciculata and zona reticularis (Stefunkova et al., 2021; Jensterle et al., 2022)
- **Pancreas**: Islet cell expression, particularly in β-cells (Müller et al., 2021)
- **Thyroid**: Follicular epithelial cell expression (Rotondi et al., 2021)
- **Pituitary gland**: Demonstrated ACE2 expression in both anterior and posterior lobes (Li et al., 2020)
- **Hypothalamus**: Detection of viral genomic sequences and ACE2 expression in postmortem studies (Abdel-Moneim & Hosni, 2021)
- **Testes and ovaries**: Significant ACE2 expression in germ cells and steroidogenic cells (Wang & Xu, 2020)

This broad endocrine tropism provides the anatomical substrate for direct viral effects on hormone-producing tissues, complementing indirect effects mediated through systemic inflammation, immune dysregulation, and vascular compromise.

1.4 Clinical Significance and Rationale for This Review

The clinical implications of SARS-CoV-2-induced adrenal dysfunction extend across multiple phases of COVID-19 illness:

- **Acute phase**: Adrenal insufficiency may contribute to hemodynamic instability, electrolyte disturbances, and increased mortality in critically ill patients. Recognition of adrenal dysfunction is essential for appropriate corticosteroid replacement therapy.
- **Subacute phase**: Persistent HPA axis abnormalities may complicate recovery, manifesting as fatigue, orthostatic hypotension, and failure to thrive.
- **Long-term sequelae**: Emerging evidence suggests that some patients may develop permanent adrenal insufficiency requiring lifelong replacement therapy, while others experience transient dysfunction with gradual recovery.

Despite growing recognition of these phenomena, significant knowledge gaps remain regarding the precise mechanisms of viral-induced adrenal injury, the natural history of HPA axis recovery, optimal diagnostic approaches, and evidence-based management strategies. This comprehensive review aims to synthesize current understanding of SARS-CoV-2 effects on cortisol secretion and glucocorticoid receptor function, providing a framework for clinical management and identifying priorities for future research.

1.5 Objectives

This review addresses the following specific objectives:

1. **To characterize** the molecular basis of SARS-CoV-2 tropism for adrenal tissue, including ACE2/TMPRSS2 expression patterns and downstream consequences of viral entry.
2. **To delineate** the multiple pathogenetic mechanisms through which SARS-CoV-2 disrupts HPA axis function, including direct cytopathic effects, central dysfunction, immune-mediated inflammation, molecular mimicry, and ACTH-cortisol dissociation.
3. **To examine** alterations in glucocorticoid receptor expression, isoform balance, and post-receptor signaling that contribute to tissue glucocorticoid resistance.
4. **To describe** the clinical spectrum of adrenal dysfunction in COVID-19, including critical illness-related corticosteroid insufficiency (CIRCI), overt adrenal insufficiency, and subclinical HPA axis abnormalities.
5. **To discuss** implications for clinical management, including diagnostic strategies, corticosteroid therapy considerations, and long-term follow-up recommendations.
6. **To identify** knowledge gaps and prioritize directions for future research in COVID-19-associated adrenal disorders.

2. MOLECULAR MECHANISMS OF SARS-COV-2 ADRENAL TROPISM

2.1 ACE2 and TMPRSS2 Expression in Adrenal Tissue

The capacity of SARS-CoV-2 to infect adrenal cells depends critically on the expression of viral entry factors on target cell surfaces. Comprehensive transcriptomic and proteomic analyses have mapped ACE2 and TMPRSS2 expression across human tissues, revealing significant adrenal expression (Li et al., 2020; Sungnak et al., 2020).

2.1.1 Adrenal ACE2 Expression

Single-cell RNA sequencing studies have demonstrated that ACE2 expression in the adrenal gland is predominantly localized to adrenocortical cells, with minimal expression in adrenal medulla (Stefunkova et al., 2021). Within the cortex, expression levels vary across functional zones:

- **Zona glomerulosa**: Moderate ACE2 expression, potentially affecting mineralocorticoid production
- **Zona fasciculata**: Highest ACE2 expression levels, implicating direct effects on cortisol synthesis
- **Zona reticularis**: Significant ACE2 expression, potentially influencing adrenal androgen production

The cellular localization of ACE2 extends beyond steroidogenic cells to include endothelial cells lining adrenal sinusoids and vascular structures, as well as occasional mesenchymal cells within the adrenal capsule and stroma (Kanczkowski et al., 2022). This broad cellular distribution suggests multiple potential pathways for viral-induced adrenal injury: direct infection of steroidogenic cells impairing hormone synthesis, endothelial infection disrupting microvascular integrity, and stromal infection potentially altering the paracrine microenvironment.

2.1.2 TMPRSS2 Co-Expression

TMPRSS2, the serine protease essential for spike protein priming, shows co-expression patterns with ACE2 in adrenal tissue, though with somewhat different cellular distribution (Jensterle et al., 2022). TMPRSS2 is particularly abundant in adrenocortical epithelial cells, where it co-localizes with ACE2 to facilitate efficient viral entry. The synergistic action of these two factors creates a permissive environment for productive viral infection of adrenocortical cells.

2.1.3 Regional and Individual Variation

Significant inter-individual variation in adrenal ACE2 expression has been documented, potentially explaining differential susceptibility to adrenal involvement among COVID-19 patients. Factors influencing expression levels may include:

- Age-related changes in adrenal physiology
- Pre-existing endocrine disorders
- Genetic polymorphisms in ACE2 regulatory regions
- Prior exposure to medications affecting the renin-angiotensin-aldosterone system
- Chronic inflammatory conditions

2.2 Viral Entry and Replication in Adrenocortical Cells

Following ACE2-mediated binding and TMPRSS2-dependent fusion, SARS-CoV-2 enters adrenocortical cells through endocytosis, releasing its genomic RNA into the cytoplasm for replication. The subsequent cascade of viral replication triggers multiple cellular responses:

- **Endoplasmic reticulum stress**: Viral protein synthesis overwhelms ER folding capacity, activating unfolded protein response pathways
- **Mitochondrial dysfunction**: Viral interference with mitochondrial function disrupts cellular energy metabolism and steroidogenesis
- **Apoptosis and necrosis**: Direct cytopathic effects may lead to cell death through both apoptotic and necrotic pathways
- **Autophagy dysregulation**: Viral manipulation of autophagic pathways may facilitate replication while impairing cellular clearance mechanisms

Evidence for productive viral replication in adrenal tissue derives from multiple sources. Autopsy studies have demonstrated SARS-CoV-2 viral particles within adrenocortical cells using electron microscopy, while RT-PCR analysis has detected viral RNA in adrenal tissue from deceased COVID-19 patients (Gu & Korteweg, 2007; Kanczkowski et al., 2022). The extent of viral replication likely correlates with the severity of adrenal injury and the magnitude of functional impairment.

2.3 Direct Cytopathic Effects and Histopathological Changes

The direct cytopathic consequences of SARS-CoV-2 adrenal infection manifest as characteristic histopathological alterations documented in multiple autopsy series (Table 1).

Table 1. Histopathological Findings in Adrenal Glands from COVID-19 Autopsy Studies

Finding	Frequency	Description	Proposed Mechanism
Acute fibrinoid necrosis	40-60%	Necrosis of small arterioles in adrenal parenchyma, capsule, and periadrenal fat	Direct endothelial injury; immune complex deposition
Subendothelial vacuolization	30-50%	Vacuolar changes in endothelial cells without significant inflammation	Viral cytopathic effect; endothelial activation
Endothelial apoptosis	20-40%	Programmed cell death of endothelial cells	Viral-induced apoptosis; cytokine-mediated injury
Parenchymal infarcts	15-25%	Coagulative necrosis of adrenocortical tissue	Thrombotic occlusion of adrenal vessels; vascular compromise
Adrenal hemorrhage	10-20%	Extravasation of blood into adrenal parenchyma	Vascular rupture; coagulopathy; venous stasis
Thrombosis	20-30%	Fibrin thrombi in adrenal vessels	Hypercoagulable state; endothelial injury; stasis

The vascular pathology observed in adrenal glands from COVID-19 patients is particularly noteworthy. The adrenal glands possess a unique vascular architecture characterized by abundant arterial supply from multiple sources (inferior phrenic, aortic, and renal arteries) converging into a single central vein (Fox, 1976). This anatomical configuration creates a vascular watershed area potentially vulnerable to ischemic injury when microvascular thrombosis compromises flow. ACTH-induced arteriolar dilation during stress responses may further exacerbate venous stasis, increasing susceptibility to infarction and hemorrhage (Wepler et al., 2020).

2.4 Adrenal Hemorrhage and Infarction

Multiple case reports and case series have documented acute adrenal hemorrhage and infarction as complications of severe COVID-19 (Sharrack et al., 2020; Leyendecker et al., 2020). These events typically present with:

- Acute-onset flank or abdominal pain
- Unexplained hypotension or shock
- Electrolyte disturbances (hyponatremia, hyperkalemia)
- Fever (may be obscured by underlying COVID-19)
- Imaging findings of adrenal enlargement, hemorrhage, or infarction on CT or MRI

The pathogenesis of adrenal hemorrhage in COVID-19 is multifactorial, involving:

- **Hypercoagulability**: COVID-19-associated coagulopathy with elevated D-dimer, fibrinogen, and von Willebrand factor promotes thrombotic events
- **Endothelial injury**: Direct viral infection of endothelial cells triggers inflammation and procoagulant changes
- **Microvascular thrombosis**: Disseminated intravascular coagulation-like picture with microthrombi in adrenal vessels
- **Venous stasis**: ACTH-induced vasodilation during stress may impair venous drainage
- **Hemorrhagic transformation**: Ischemic areas may undergo hemorrhagic conversion

The clinical significance of adrenal hemorrhage extends beyond acute presentation; patients may develop permanent adrenal insufficiency requiring lifelong glucocorticoid and mineralocorticoid replacement therapy.

2.5 Correlation with Clinical Severity

The extent of adrenal pathology correlates broadly with COVID-19 severity. Patients with severe or critical illness demonstrate more pronounced adrenal histopathological changes compared to those with mild or moderate disease (Kanczkowski et al., 2022). This relationship likely reflects:

- Higher viral loads in severe disease, leading to greater direct viral cytopathic effects
- More intense systemic inflammation with cytokine storm exacerbating tissue injury
- Greater hemodynamic instability and coagulopathy promoting vascular complications
- Increased stress on the HPA axis, potentially unmasking subclinical adrenal compromise

Understanding this correlation has important implications for risk stratification and monitoring. Patients with severe COVID-19 may warrant closer endocrine surveillance, both during acute illness and following recovery.

3. CENTRAL HPA AXIS DYSFUNCTION IN COVID-19

3.1 Hypothalamic and Pituitary Involvement

While direct adrenal infection provides one pathway to cortisol dysregulation, accumulating evidence indicates that central components of the HPA axis—the hypothalamus and pituitary gland—are also targets of SARS-CoV-2. This central involvement may lead to secondary adrenal insufficiency, with implications for diagnosis and management distinct from primary adrenal failure.

3.1.1 ACE2 Expression in Hypothalamus and Pituitary

Both the hypothalamus and pituitary gland express ACE2 and TMPRSS2, rendering them potentially susceptible to direct viral infection (Li et al., 2020; Abdel-Moneim & Hosni, 2021). Within the hypothalamus, ACE2 expression has been documented in:

- Paraventricular nucleus neurons (CRH-producing cells)
- Supraoptic nucleus neurons
- Arcuate nucleus neurons
- Tanycytes lining the third ventricle

Pituitary ACE2 expression is distributed across both anterior and posterior lobes, with particularly high levels in corticotroph cells (ACTH-producing) and somatotroph cells (growth hormone-producing) (Fara et al., 2021).

3.1.2 Evidence for Direct Viral Invasion

Multiple lines of evidence support direct SARS-CoV-2 invasion of hypothalamic-pituitary tissues:

- **Genomic detection**: Viral RNA sequences have been amplified from hypothalamic and pituitary tissue in postmortem studies (Abdel-Moneim & Hosni, 2021)
- **Immunohistochemistry**: Viral spike and nucleocapsid proteins have been localized to hypothalamic neurons and pituitary cells
- **Electron microscopy**: Visualization of viral particles within hypothalamic and pituitary tissue
- **Histopathology**: Documentation of necrosis, infarction, and inflammatory infiltrates in pituitary glands from COVID-19 decedents

These findings parallel observations from the SARS-CoV-1 epidemic, where autopsy studies demonstrated reduced corticotroph cell counts and altered ACTH immunoreactivity in pituitary glands (Leow et al., 2005).

3.2 Central Hypocortisolism: Clinical Evidence

The functional consequences of central HPA axis involvement manifest as biochemical evidence of secondary adrenal insufficiency. Several studies have documented HPA axis abnormalities in COVID-19 patients and survivors.

3.2.1 Acute Phase Findings

During acute COVID-19 illness, multiple investigators have reported evidence of central hypocortisolism (Alzahrani et al., 2020; Mao et al., 2020):

- Low or inappropriately normal ACTH levels despite critical illness
- Subnormal cortisol responses to ACTH stimulation testing
- Preservation of aldosterone secretion (distinguishing from primary adrenal failure)
- Absence of hyperpigmentation (characteristic of primary adrenal insufficiency)

These findings suggest that in a subset of patients, the HPA axis fails to mount the expected stress response, potentially contributing to hemodynamic instability and increased mortality risk.

3.2.2 Post-Recovery Findings

Longitudinal follow-up of COVID-19 survivors has provided additional evidence for transient central HPA axis dysfunction. Leow et al. (2005) followed survivors of SARS-CoV-1 infection and documented hypocortisolism in approximately 40% of patients at three months post-recovery. Notably, this

dysfunction was predominantly central in origin (low ACTH levels) and resolved within one year in two-thirds of affected individuals.

Subsequent studies in COVID-19 survivors have reported similar findings (Hashim et al., 2021; Kanczkowski et al., 2022):

- Prevalence of central hypocortisolism ranging from 15-40% at 3-6 months post-recovery
- Gradual improvement in HPA axis function over 6-12 months
- Complete recovery in most patients, though a subset may have persistent dysfunction

The transient nature of central hypocortisolism in most patients argues against permanent structural damage and favors mechanisms such as:

- Reversible neuronal dysfunction rather than cell death
- Suppression of CRH/ACTH secretion by inflammatory cytokines
- Delayed recovery of HPA axis set-point following critical illness

3.3 Immune-Mediated Hypophysitis

Beyond direct viral cytopathic effects, immune-mediated inflammation may contribute to pituitary dysfunction in COVID-19. Several lines of evidence support this mechanism:

3.3.1 Cytokine Effects on Pituitary Function

Proinflammatory cytokines elevated during COVID-19 cytokine storm—including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)—have well-documented effects on pituitary hormone secretion (Kunz-Ebrecht et al., 2003; Glaser & Kiecolt-Glaser, 2005):

- **IL-1**: Suppresses CRH-stimulated ACTH secretion; may directly inhibit pituitary corticotroph function
- **IL-6**: Complex bidirectional effects—acutely stimulates ACTH but chronic elevation may suppress responsiveness
- **TNF-α**: Inhibits ACTH secretion and may induce corticotroph apoptosis

The cytokine milieu characteristic of severe COVID-19 thus creates conditions favoring pituitary suppression, potentially contributing to central hypocortisolism.

3.3.2 Autoimmune Hypophysitis

Case reports have documented new-onset autoimmune hypophysitis following COVID-19 infection (Fara et al., 2021). Proposed mechanisms include:

- **Molecular mimicry**: Viral antigens resembling pituitary self-antigens trigger cross-reactive immune responses
- **Bystander activation**: Viral-induced inflammation exposes sequestered pituitary antigens to immune recognition
- **Epitope spreading**: Initial immune response to viral antigens expands to include pituitary autoantigens

Autoimmune hypophysitis typically presents with headache, visual disturbances, and varying degrees of pituitary hormone deficiencies. Diagnosis requires high index of suspicion and appropriate imaging (pituitary MRI showing enlargement and/or stalk thickening).

3.4 Pituitary Apoplexy

Pituitary apoplexy—hemorrhage or infarction of the pituitary gland—represents a rare but life-threatening complication that may be precipitated by COVID-19 infection (Fara et al., 2021). Risk factors for COVID-19-associated pituitary apoplexy include:

- Pre-existing pituitary adenoma (particularly non-functioning or prolactin-secreting macroadenomas)
- Anticoagulant therapy (increased hemorrhage risk)
- Severe COVID-19 with systemic inflammation and coagulopathy
- Dopamine agonist therapy for prolactinomas (may increase apoplexy risk)

The pathophysiological basis involves increased metabolic demand on pituitary tissue during stress, combined with COVID-19-associated endothelial dysfunction and coagulopathy, potentially compromising vascular supply to the pituitary gland.

Clinical presentation of pituitary apoplexy includes:

- Sudden severe headache
- Visual field defects (typically bitemporal hemianopia)
- Ophthalmoplegia (cranial nerve palsies)
- Nausea and vomiting
- Altered mental status
- Acute adrenal crisis (if ACTH deficiency develops)

Emergency management requires high-dose glucocorticoid replacement and neurosurgical consultation for possible decompression.

3.5 Dissociation of ACTH and Cortisol Regulation

An important concept in understanding HPA axis dysfunction during critical illness, including severe COVID-19, is the phenomenon of ACTH-cortisol dissociation (Jensterle et al., 2022). Under normal physiological conditions, cortisol secretion is tightly regulated by ACTH through negative feedback loops. However, during severe illness, multiple ACTH-independent mechanisms can influence cortisol levels:

3.5.1 Cytokine-Driven Cortisol Secretion

Proinflammatory cytokines, particularly IL-6, can directly stimulate adrenal cortisol production through:

- Upregulation of adrenal steroidogenic enzyme expression
- Sensitization of adrenal cells to ACTH stimulation
- Direct activation of adrenal signaling pathways

This ACTH-independent stimulation may explain observations of elevated cortisol with inappropriately low ACTH in some severely ill COVID-19 patients.

3.5.2 Reduced Cortisol Clearance

Critical illness is associated with reduced hepatic and renal clearance of cortisol, prolonging its half-life and elevating circulating levels. Mechanisms include:

- Downregulation of cortisol-metabolizing enzymes (11β-hydroxysteroid dehydrogenase type 2, 5α-reductase)
- Reduced hepatic blood flow
- Impaired renal function

The resulting elevation in cortisol feeds back to suppress ACTH, contributing to the dissociation phenomenon.

3.5.3 Altered Corticosteroid-Binding Globulin

Corticosteroid-binding globulin (CBG), the primary carrier protein for cortisol, may be reduced during critical illness due to:

- Hepatic dysfunction reducing synthesis
- Increased clearance through neutrophil elastase cleavage at inflammatory sites
- Capillary leak syndrome with extravascular loss

Reduced CBG increases free cortisol fraction, potentially elevating biologically active hormone despite normal or even low total cortisol measurements.

3.5.4 Tissue-Specific Cortisol Regeneration

11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts inactive cortisone to active cortisol within target tissues. This enzyme is upregulated in inflammatory states, potentially increasing local cortisol availability independent of circulating levels.

The clinical implication of ACTH-cortisol dissociation is that standard diagnostic approaches relying on random cortisol or ACTH measurements may misclassify HPA axis status. Dynamic testing (ACTH stimulation tests) and assessment of free cortisol may provide more accurate assessment in critically ill patients.

4. GLUCOCORTICOID RECEPTOR SIGNALING IN COVID-19

4.1 Glucocorticoid Receptor Structure and Function

The biological actions of cortisol are mediated primarily through the intracellular glucocorticoid receptor (GR), a member of the nuclear receptor superfamily of transcription factors. Understanding GR biology is essential for interpreting the tissue effects of cortisol in COVID-19 patients, as receptor-level alterations can profoundly influence glucocorticoid responsiveness independent of circulating hormone levels.

4.1.1 GR Gene and Isoforms

The human glucocorticoid receptor gene (NR3C1) is located on chromosome 5q31-32 and comprises 9 exons (Bamberger, Schulte, & Chrousos, 1996). Alternative splicing of exon 9 generates two highly homologous isoforms:

- **GR-α**: The classic glucocorticoid receptor, comprising 777 amino acids, functions as a ligand-dependent transcription factor mediating most glucocorticoid actions
- **GR-β**: A 742-amino acid isoform that does not bind glucocorticoids and exerts dominant-negative inhibition of GR-α transcriptional activity

The balance between GR-α and GR-β expression critically determines cellular glucocorticoid sensitivity. Increased GR-β expression has been implicated in glucocorticoid resistance in various inflammatory conditions, including asthma, rheumatoid arthritis, and sepsis.

4.1.2 GR Domain Structure

Both GR isoforms share common structural domains:

- **N-terminal domain**: Contains activation function-1 (AF-1), mediating ligand-independent transcriptional activity and interactions with co-regulatory proteins
- **DNA-binding domain**: Contains two zinc finger motifs mediating receptor dimerization and binding to glucocorticoid response elements (GREs) in target gene promoters
- **Hinge region**: Flexible linker connecting DNA-binding and ligand-binding domains
- **Ligand-binding domain**: C-terminal domain containing hormone-binding pocket, nuclear localization signals, and activation function-2 (AF-2) for ligand-dependent co-activator recruitment

4.1.3 GR Signaling Pathway

The canonical GR signaling pathway involves (Figure 1):

1. **Ligand binding**: Cortisol diffuses across the cell membrane and binds to cytoplasmic GR complexed with heat shock proteins (HSP90, HSP70) and immunophilins
2. **Nuclear translocation**: Ligand binding induces conformational changes exposing nuclear localization signals, promoting GR nuclear import
3. **DNA binding**: Nuclear GR homodimers bind to GREs in target gene promoters—palindromic sequences typically characterized by consensus motif GGTACAnnnTGTTCT
4. **Transcriptional regulation**: GR recruits co-activators (e.g., steroid receptor co-activator-1, CREB-binding protein) or co-repressors (e.g., nuclear receptor co-repressor) to modulate gene expression

GR regulates gene expression through multiple mechanisms:

- **Transactivation**: Direct binding to GREs enhances transcription of anti-inflammatory genes (e.g., IκBα, IL-10, annexin A1)
- **Transrepression**: GR interferes with proinflammatory transcription factors (NF-κB, AP-1) through protein-protein interactions, suppressing inflammatory gene expression
- **Tethered transrepression**: GR binds to other transcription factors without directly contacting DNA
- **Composite GREs**: GR interacts with other transcription factors on composite response elements

4.2 Glucocorticoid Receptor Alterations in COVID-19

Emerging evidence indicates that SARS-CoV-2 infection and the associated inflammatory response induce significant alterations in GR expression and function, contributing to tissue glucocorticoid resistance.

4.2.1 Reduced GR-α Expression

Several studies have documented reduced GR-α expression in cells from COVID-19 patients (Jensterle et al., 2022; Ilias et al., 2023):

- **Bronchoalveolar lavage cells**: Sequencing data from patients with severe COVID-19 demonstrated reduced GR-α mRNA compared to mild cases
- **Peripheral blood mononuclear cells**: Decreased GR-α protein expression in critically ill COVID-19 patients
- **Postmortem tissues**: Reduced GR immunostaining in lung and adrenal tissues from COVID-19 decedents

The degree of GR-α downregulation correlates with disease severity, suggesting that loss of this key mediator of glucocorticoid anti-inflammatory effects may contribute to uncontrolled inflammation and poor outcomes.

4.2.2 Increased GR-β Expression

Parallel studies have documented increased GR-β expression in COVID-19 patients (Annane et al., 2017; Ilias et al., 2023):

- **Peripheral blood**: Elevated GR-β mRNA in circulating leukocytes from severe COVID-19 patients
- **Tissue samples**: Increased GR-β immunostaining in inflamed tissues
- **GR-α/GR-β ratio**: Markedly reduced ratio favoring GR-β in severe disease

Given GR-β's dominant-negative effects on GR-α transcriptional activity, increased GR-β expression may compound the functional deficit created by reduced GR-α, further impairing glucocorticoid responsiveness.

4.2.3 Altered GR Phosphorylation and Post-Translational Modifications

GR function is modulated by multiple post-translational modifications that may be altered in COVID-19:

- **Phosphorylation**: GR is phosphorylated at multiple serine residues by various kinases (cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinase-3β), affecting nuclear translocation, DNA binding, and transcriptional activity
- **Sumoylation**: Covalent attachment of small ubiquitin-like modifier (SUMO) proteins modulates GR stability and transcriptional activity
- **Ubiquitination**: GR ubiquitination targets the receptor for proteasomal degradation, regulating receptor half-life
- **Acetylation**: Histone acetyltransferases and deacetylases modulate GR function through acetylation of lysine residues

Inflammatory cytokines elevated in COVID-19 activate signaling pathways (p38 MAPK, JNK, IKK) that can phosphorylate GR, potentially altering its function and contributing to glucocorticoid resistance.

4.3 Mechanisms of Glucocorticoid Resistance

The observed alterations in GR expression and function contribute to a state of relative glucocorticoid resistance in COVID-19, characterized by inadequate anti-inflammatory response despite adequate cortisol levels (Table 2).

Table 2. Mechanisms of Glucocorticoid Resistance in COVID-19

Mechanism	Description	Clinical Consequence
Reduced GR-α expression	Decreased receptor number per cell	Diminished glucocorticoid signaling capacity
Increased GR-β expression	Dominant-negative inhibition of GR-α	Functional antagonism of residual GR-α
Altered GR phosphorylation	Changes in receptor phosphorylation state	Impaired nuclear translocation and DNA binding
Cytokine-mediated GR inhibition	Proinflammatory cytokines interfere with GR function	Transrepression failure
NF-κB/GR antagonism	Activated NF-κB sequesters GR and co-activators	Reduced anti-inflammatory gene expression
Impaired GR nuclear translocation	Failure of ligand-bound GR to enter nucleus	Loss of genomic glucocorticoid effects
Altered co-regulator expression	Changes in co-activator/co-repressor balance	Dysregulated GR target gene expression

4.3.1 Cytokine-GR Interactions

Proinflammatory cytokines elevated in COVID-19 can directly interfere with GR function through multiple pathways:

- **p38 MAPK activation**: IL-1 and TNF-α activate p38 MAPK, which phosphorylates GR and inhibits nuclear translocation
- **STAT family members**: Cytokine-activated STAT proteins compete with GR for limited co-activators (CBP/p300)
- **NF-κB sequestration**: Activated NF-κB physically interacts with GR, preventing DNA binding and transactivation
- **AP-1 interference**: c-Jun/c-Fos complexes bind GR, inhibiting GRE binding and transactivation

4.3.2 GR Nuclear Translocation Defects

Efficient nuclear translocation of ligand-bound GR is essential for genomic glucocorticoid effects. Several factors in COVID-19 may impair this process:

- **Oxidative stress**: Reactive oxygen species can modify GR, inhibiting nuclear import
- **Nitric oxide**: Excessive NO production may S-nitrosylate GR, altering function
- **Hypoxia**: Tissue hypoxia from severe COVID-19 may impair energy-dependent nuclear transport
- **Inflammatory signaling**: Cytokine-activated kinases may phosphorylate GR, masking nuclear localization signals

4.4 Clinical Implications of Glucocorticoid Resistance

The development of glucocorticoid resistance in COVID-19 has important clinical implications:

4.4.1 Implications for Endogenous Cortisol

Patients with glucocorticoid resistance may exhibit:

- Elevated cortisol levels (compensatory increase) yet inadequate anti-inflammatory effect
- Persistent inflammation despite biochemical evidence of HPA axis activation
- Poor correlation between cortisol levels and clinical status
- Exaggerated ACTH responses to stimulation testing (due to reduced feedback sensitivity)

4.4.2 Implications for Exogenous Corticosteroid Therapy

Glucocorticoid resistance may explain the variable responses to corticosteroid therapy observed in COVID-19 clinical trials:

- **Non-responders**: Patients with severe resistance may show minimal benefit from standard corticosteroid doses
- **Delayed response**: Overcoming resistance may require higher doses or prolonged treatment
- **Rebound inflammation**: Rapid corticosteroid withdrawal may unmask persistent inflammation

The RECOVERY trial demonstrated mortality benefit with dexamethasone specifically in patients requiring respiratory support (oxygen or mechanical ventilation) but not in milder cases (RECOVERY Collaborative Group, 2021). This differential response may reflect, in part, differences in glucocorticoid resistance severity across disease stages.

4.4.3 Personalized Medicine Implications

Assessment of GR expression and function could potentially guide corticosteroid therapy:

- **GR-α/GR-β ratio**: May identify patients likely to respond to corticosteroid therapy
- **GR phosphorylation status**: Could indicate degree of inflammatory interference with GR function
- **In vitro glucocorticoid sensitivity assays**: May predict clinical response

However, these approaches remain investigational and require validation before clinical implementation.

4.5 Tissue-Specific Considerations

Glucocorticoid sensitivity varies across tissues, influenced by:

- **Local cortisol availability**: 11β-HSD1 expression determines local cortisol regeneration
- **GR isoform expression**: Tissue-specific GR-α/GR-β ratios influence responsiveness
- **Co-regulator expression**: Cell-specific co-activator/co-repressor profiles modulate GR transcriptional output
- **Inflammatory milieu**: Local cytokine environment differentially affects GR function

In COVID-19, tissue-specific glucocorticoid resistance may contribute to organ-specific manifestations. For example:

- **Lung**: Pulmonary inflammation may be particularly resistant to glucocorticoid effects due to intense local cytokine production and GR alterations in alveolar cells
- **Adrenal**: GR resistance in adrenocortical cells may impair negative feedback regulation, contributing to HPA axis dysregulation
- **Immune cells**: Differential GR sensitivity across lymphocyte subsets may alter Th1/Th2 balance and immune response polarization

5. CLINICAL SPECTRUM OF ADRENAL DYSFUNCTION IN COVID-19

5.1 Critical Illness-Related Corticosteroid Insufficiency (CIRCI)

Critical illness-related corticosteroid insufficiency (CIRCI) represents a syndrome of inadequate cellular corticosteroid activity for the severity of a patient's illness, resulting from dysfunction of the HPA axis and/or tissue glucocorticoid resistance (Annane et al., 2017). CIRCI has been well-characterized in sepsis, ARDS, and other critical illnesses, and emerging evidence indicates its frequent occurrence in severe COVID-19.

5.1.1 Definition and Diagnostic Criteria

The 2017 Society of Critical Care Medicine/European Society of Intensive Care Medicine consensus definition identifies CIRCI based on:

- **Clinical context**: Critical illness with systemic inflammation (sepsis, ARDS, severe trauma, major surgery)
- **Biochemical criteria**:
    - Random total cortisol < 10 μg/dL (276 nmol/L)
    - Delta cortisol < 9 μg/dL (248 nmol/L) after 250 μg cosyntropin stimulation
    - Free cortisol < 2 μg/dL (55 nmol/L) (if available)

Alternative approaches include measurement of cortisol response to 1 μg cosyntropin or assessment of salivary cortisol, though these require further validation in COVID-19.

5.1.2 CIRCI in COVID-19

Multiple studies have documented CIRCI in severe COVID-19 patients (Hakan et al., 2021; Ilias et al., 2023):

- **Prevalence**: Estimates range from 20-60% of critically ill COVID-19 patients, varying with illness severity and diagnostic criteria
- **Risk factors**: Greater prevalence in patients requiring mechanical ventilation, with ARDS, or with septic shock
- **Mortality association**: CIRCI predicts increased mortality and prolonged ICU stay
- **Timing**: May develop early in critical illness course or evolve over time

The pathogenesis of CIRCI in COVID-19 reflects the multiple mechanisms discussed previously:

- Direct adrenal injury (infarction, hemorrhage, inflammation)
- Central HPA axis suppression
- Glucocorticoid resistance
- Altered cortisol metabolism
- Cytokine-mediated HPA dysfunction

5.1.3 Clinical Presentation

CIRCI in COVID-19 may manifest as:

- **Vasopressor-dependent shock**: Hypotension requiring high-dose vasopressors despite adequate fluid resuscitation
- **Unexplained fever**: Persistent fever without identifiable infectious source
- **Electrolyte disturbances**: Hyponatremia (from impaired free water excretion), hyperkalemia (if mineralocorticoid deficiency coexists)
- **Hypoglycemia**: Particularly in patients with limited glycogen reserves
- **Eosinophilia**: Relative eosinophilia despite critical illness
- **Delayed weaning from mechanical ventilation**: Prolonged respiratory failure

Recognition of CIRCI is crucial because it represents a potentially treatable condition—corticosteroid replacement may improve hemodynamics and facilitate recovery.

5.1.4 Management of CIRCI in COVID-19

Current guidelines for CIRCI management in COVID-19 patients recommend (Annane et al., 2017; RECOVERY Collaborative Group, 2021):

- **Hydrocortisone**: 200 mg/day continuous infusion or divided doses (50 mg IV q6h) for 5-7 days, then taper
- **Alternative**: Dexamethasone 6 mg/day (as per RECOVERY trial protocol) provides both glucocorticoid replacement and anti-inflammatory effects
- **Monitoring**: Clinical response (hemodynamics, vasopressor requirements, gas exchange) rather than repeat cortisol measurements

- **Duration**: Limited course (5-10 days) to minimize adverse effects while providing benefit

The optimal corticosteroid regimen in COVID-19-associated CIRCI remains debated, with some experts favoring hydrocortisone for its mineralocorticoid activity and rapid titratability, while others cite dexamethasone's mortality benefit demonstrated in RECOVERY.

5.2 Overt Adrenal Insufficiency

Beyond CIRCI, a subset of COVID-19 patients develops overt adrenal insufficiency requiring long-term hormone replacement.

5.2.1 Primary Adrenal Insufficiency

Primary adrenal insufficiency (Addison's disease) results from destruction or dysfunction of the adrenal cortex itself. COVID-19-associated primary adrenal insufficiency may result from:

- **Bilateral adrenal hemorrhage**: Acute onset with adrenal crisis presentation
- **Adrenal infarction**: Ischemic necrosis from vascular occlusion
- **Extensive viral infection**: Diffuse viral cytopathic effects destroying adrenocortical tissue
- **Autoimmune adrenalitis**: Post-infectious autoimmune destruction

Clinical features include:

- Hyperpigmentation (mucocutaneous, palmar creases, scars)
- Salt craving
- Postural hypotension
- Hyponatremia, hyperkalemia
- Elevated ACTH (typically >100 pg/mL)
- Low cortisol with blunted or absent ACTH stimulation response
- Aldosterone deficiency (elevated renin, normal or low aldosterone)

5.2.2 Secondary Adrenal Insufficiency

Secondary adrenal insufficiency results from inadequate ACTH secretion due to hypothalamic or pituitary dysfunction. COVID-19-associated secondary adrenal insufficiency may arise from:

- Direct hypothalamic or pituitary viral infection
- Pituitary apoplexy
- Autoimmune hypophysitis
- Cytokine-mediated suppression
- Exogenous corticosteroid-induced suppression

Clinical features differ from primary insufficiency:

- Absence of hyperpigmentation
- Preserved mineralocorticoid function (typically normal electrolytes)
- Low or inappropriately normal ACTH
- Associated deficiencies of other pituitary hormones (hypothyroidism, hypogonadism) if extensive pituitary damage

5.2.3 Diagnosis

Diagnosis of adrenal insufficiency in COVID-19 patients requires high index of suspicion and appropriate testing:

- **Morning cortisol**: < 3 μg/dL (83 nmol/L) suggests adrenal insufficiency; > 15 μg/dL (414 nmol/L) makes it unlikely
- **ACTH stimulation test**: 250 μg cosyntropin with cortisol measured at 0, 30, and 60 minutes; peak < 18 μg/dL (500 nmol/L) indicates adrenal insufficiency
- **Plasma ACTH**: Distinguishes primary (elevated) from secondary (low/inappropriately normal)
- **Aldosterone/renin**: Assess mineralocorticoid axis in suspected primary insufficiency
- **Imaging**: Adrenal CT for morphology (hemorrhage, infiltration, atrophy); pituitary MRI if central cause suspected

Important caveats in COVID-19 patients:

- Critical illness may elevate cortisol, potentially masking insufficiency
- Hypoalbuminemia reduces total cortisol; free cortisol measurement may be more accurate
- Cytokine effects may cause ACTH-cortisol dissociation, complicating interpretation

5.2.4 Management

Established adrenal insufficiency requires hormone replacement therapy:

- **Glucocorticoid replacement**:
  - Hydrocortisone 15-25 mg/day in divided doses (typically 10 mg on awakening, 5 mg at midday, 5 mg late afternoon)
  - Prednisolone 3-5 mg once daily (alternative)
  - Stress dosing during intercurrent illness (double or triple maintenance doses)
- **Mineralocorticoid replacement** (primary insufficiency only):
  - Fludrocortisone 0.05-0.2 mg/day
  - Monitor electrolytes, blood pressure, and renin for dose adjustment
- **Patient education**:
  - Sick day rules
  - Emergency injectable hydrocortisone kit
  - Medical alert identification

Patients with transient adrenal insufficiency require periodic reassessment to determine whether recovery has occurred and replacement can be withdrawn.

5.3 Subclinical HPA Axis Abnormalities

Beyond overt adrenal insufficiency, many COVID-19 patients exhibit subclinical HPA axis abnormalities that may not require immediate treatment but warrant observation.

5.3.1 Mild HPA Suppression

Some recovered patients demonstrate:

- Normal basal cortisol but blunted ACTH stimulation response
- Preserved clinical stability without glucocorticoid therapy
- Potential vulnerability to adrenal crisis under future stress

These patients should receive education regarding "stress dosing" during intercurrent illness and may benefit from periodic reassessment.

5.3.2 Altered Diurnal Rhythm

COVID-19 survivors may exhibit disrupted cortisol diurnal variation:

- Blunted morning peak
- Elevated evening nadir
- Altered cortisol awakening response

These changes may contribute to persistent fatigue, sleep disturbance, and mood disorders observed in long COVID syndrome.

5.3.3 Altered Feedback Sensitivity

Some patients demonstrate altered glucocorticoid feedback sensitivity:

- Dexamethasone suppression test abnormalities
- Inadequate cortisol suppression following exogenous glucocorticoid
- Potential contribution to persistent inflammation

5.4 Long-Term Sequelae and Recovery Patterns

The natural history of COVID-19-associated adrenal dysfunction remains incompletely characterized, but emerging data suggest variable recovery patterns:

5.4.1 Recovery from CIRCI

Most patients with CIRCI recover normal HPA axis function following resolution of critical illness:

- Time course: Days to weeks following recovery from acute illness
- Predictors of recovery: Less severe initial illness, absence of structural adrenal damage
- Monitoring: Repeat ACTH stimulation testing before hospital discharge or during follow-up

5.4.2 Recovery from Transient Central Hypocortisolism

As noted previously, approximately two-thirds of patients with post-COVID central hypocortisolism recover within one year (Hashim et al., 2021):

- **Early recovery** (3-6 months): Gradual increase in morning cortisol and ACTH
- **Late recovery** (6-12 months): Normalization of ACTH stimulation testing
- **Non-recovery**: Persistent abnormalities requiring ongoing replacement

5.4.3 Permanent Adrenal Insufficiency

Patients with structural adrenal damage (bilateral hemorrhage, extensive infarction) may develop permanent adrenal insufficiency requiring lifelong replacement. Factors predicting permanent damage include:

- Extensive bilateral adrenal abnormalities on imaging
- Severe initial presentation with adrenal crisis
- Associated autoimmunity (positive adrenal antibodies)
- Lack of recovery after 12-18 months

5.4.4 Long COVID and HPA Axis Dysfunction

The syndrome of "long COVID" or post-acute sequelae of SARS-CoV-2 infection (PASC) includes symptoms potentially related to HPA axis dysfunction:

- Persistent fatigue
- Orthostatic intolerance
- Mood disturbances (anxiety, depression)
- Cognitive dysfunction ("brain fog")
- Sleep disturbances
- Myalgia and arthralgia

Whether these symptoms reflect ongoing HPA axis abnormalities or represent separate pathophysiological processes remains under investigation. Preliminary studies suggest subtle HPA axis alterations in some long COVID patients, but causality remains unproven.

6. CORTISOL-IMMUNE SYSTEM INTERPLAY IN COVID-19

6.1 The Bidirectional Relationship

Cortisol and the immune system engage in complex bidirectional communication essential for maintaining homeostasis during infection and inflammation. This relationship is particularly relevant in COVID-19, where both excessive inflammation (cytokine storm) and relative immunosuppression may coexist at different disease stages.

6.1.1 Immune Effects on Cortisol Secretion

As discussed previously, inflammatory cytokines stimulate the HPA axis through multiple mechanisms:

- **Hypothalamic level**: IL-1, IL-6, and TNF-α stimulate CRH secretion
- **Pituitary level**: Cytokines directly stimulate ACTH secretion and sensitize corticotrophs to CRH
- **Adrenal level**: IL-6 directly stimulates cortisol production and upregulates steroidogenic enzymes

The resulting cortisol elevation serves as a negative feedback mechanism to limit inflammation—a classic endocrine-immune regulatory loop.

6.1.2 Cortisol Effects on Immune Function

Cortisol exerts pleiotropic effects on immune cells (Table 3), generally suppressing proinflammatory responses while enhancing 某些 anti-inflammatory and humoral responses.

Table 3. Immunomodulatory Effects of Cortisol

Cell Type	Effects	Functional Consequence
Neutrophils	Increased release from bone marrow; decreased apoptosis; impaired chemotaxis and phagocytosis	Neutrophilia; reduced tissue infiltration
Macrophages	Decreased proinflammatory cytokine production (IL-1, IL-6, TNF-α); reduced MHC class II expression; impaired phagocytosis	Suppressed antigen presentation; reduced inflammatory mediator release
Dendritic cells	Impaired maturation; reduced antigen presentation; decreased IL-12 production	Altered T-cell priming
T lymphocytes	Apoptosis of immature and activated T cells; Th1 to Th2 shift; reduced IL-2 production	Lymphopenia; altered T-helper balance
B lymphocytes	Impaired proliferation; decreased immunoglobulin production; altered class switching	Suppressed humoral immunity
Natural killer cells	Decreased cytotoxicity; reduced cytokine production	Impaired innate antiviral immunity
Endothelial cells	Decreased adhesion molecule expression; reduced vascular permeability	Reduced leukocyte extravasation

6.1.3 The Regulatory Loop in COVID-19

In severe COVID-19, this regulatory loop may become dysregulated at multiple points:

1. **Excessive cytokine production**: Massive inflammatory response overwhelms normal feedback mechanisms
2. **Impaired cortisol production**: Adrenal dysfunction limits appropriate cortisol elevation
3. **Glucocorticoid resistance**: Target tissues fail to respond adequately to circulating cortisol
4. **Feedback resistance**: Impaired glucocorticoid feedback allows continued inflammation despite elevated cortisol

The net effect is inadequate restraint of inflammation, contributing to cytokine storm and tissue damage.

6.2 Th1/Th2 Balance and Cortisol

Cortisol promotes a shift from Th1 (cell-mediated) to Th2 (humoral) immune responses, with implications for antiviral defense and disease progression.

6.2.1 Normal Th1/Th2 Balance

- **Th1 responses**: Characterized by IFN-γ, IL-2, and TNF-β production; essential for antiviral immunity and intracellular pathogen clearance
- **Th2 responses**: Characterized by IL-4, IL-5, IL-10, and IL-13 production; promote humoral immunity and anti-helminth responses; suppress Th1 activity

6.2.2 COVID-19-Associated Th1/Th2 Dysregulation

Studies have documented altered T-helper responses in COVID-19 patients (Gil-Etayo et al., 2021; Hosseini et al., 2022):

- **Th1 suppression**: Reduced IFN-γ production and Th1 cell numbers in severe disease
- **Th2 enhancement**: Increased IL-4, IL-5, and IL-10 in some patients
- **Mixed patterns**: Considerable heterogeneity, with some patients showing Th17 predominance

Cortisol's Th1-suppressive effects may contribute to inadequate antiviral responses, particularly if endogenous cortisol elevation is excessive or prolonged.

6.2.3 Lymphopenia and Cortisol

Lymphopenia is a hallmark of severe COVID-19, affecting CD4+ and CD8+ T cells, NK cells, and B cells (Gil-Etayo et al., 2021). Cortisol contributes to lymphopenia through:

- **Apoptosis**: Glucocorticoid-induced apoptosis of immature and activated lymphocytes
- **Redistribution**: Cortisol promotes lymphocyte egress from circulation to lymphoid tissues
- **Impaired proliferation**: Inhibition of IL-2-driven T-cell proliferation

The extent of lymphopenia correlates with disease severity and may predict adverse outcomes. Whether lymphopenia represents appropriate feedback regulation to limit inflammation or pathological immunosuppression remains debated.

6.3 Cytokine Storm and Cortisol Dynamics

Cytokine storm—the uncontrolled release of proinflammatory mediators—represents a critical juncture in COVID-19 pathogenesis, often heralding clinical deterioration and progression to ARDS and multi-organ failure.

6.3.1 Cytokine Profile in Severe COVID-19

Severe COVID-19 is characterized by elevated levels of:

- IL-1β, IL-6, TNF-α (classic proinflammatory cytokines)
- IL-8 (neutrophil chemoattractant)
- IL-10 (anti-inflammatory, but also Th2-promoting)
- IFN-γ (Th1 cytokine, though often suppressed relative to others)
- MCP-1 (monocyte chemoattractant)
- G-CSF (granulocyte colony-stimulating factor)

6.3.2 Cortisol Responses During Cytokine Storm

The cortisol response during cytokine storm is variable:

- **Inadequate response**: Some patients fail to mount appropriate cortisol elevation, contributing to uncontrolled inflammation
- **Excessive response**: Others show marked cortisol elevation, potentially contributing to lymphopenia and immunosuppression
- **Delayed response**: Cortisol elevation may occur late, after inflammation has already caused tissue damage
- **Unsustained response**: Cortisol levels may fall as adrenal exhaustion develops

6.3.3 Therapeutic Implications

The complex relationship between cortisol and cytokine storm informs therapeutic strategies:

- **Corticosteroid therapy**: Aimed at suppressing excessive inflammation, but risks impairing antiviral immunity if administered too early or at excessive doses
- **Timing matters**: RECOVERY trial demonstrated benefit with dexamethasone specifically in patients requiring respiratory support (late disease), not in early disease (RECOVERY Collaborative Group, 2021)
- **Individualized approaches**: Future strategies may target therapy based on inflammatory biomarkers (CRP, IL-6) and HPA axis assessment

6.4 Glucocorticoid Therapy in COVID-19: Evidence and Controversies

6.4.1 RECOVERY Trial and Subsequent Evidence

The RECOVERY trial (Randomised Evaluation of COVID-19 Therapy) provided the first definitive evidence for corticosteroid benefit in COVID-19 (RECOVERY Collaborative Group, 2021):

- **Design**: Open-label, randomized controlled trial of dexamethasone 6 mg daily for up to 10 days vs. usual care
- **Population**: 6,425 hospitalized COVID-19 patients
- **Results**:
    - 28-day mortality reduced in patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio 0.64)
    - Mortality reduced in patients receiving oxygen without ventilation (23.3% vs. 26.2%; rate ratio 0.82)
    - No benefit (possible harm) in patients not requiring respiratory support (17.8% vs. 14.0%; rate ratio 1.19)

Subsequent meta-analyses (WHO REACT Working Group, 2020) confirmed these findings, establishing corticosteroids as standard of care for severe COVID-19.

6.4.2 Mechanism of Benefit

The mortality benefit observed likely reflects multiple mechanisms:

- **Suppression of cytokine storm**: Reducing damaging inflammation
- **Prevention of ARDS progression**: Limiting lung injury
- **CIRCI correction**: Replacing deficient cortisol in patients with adrenal dysfunction
- **Glucocorticoid resistance overcoming**: Supraphysiologic doses may overcome tissue resistance

6.4.3 Timing and Dosing Considerations

Optimal corticosteroid use requires careful consideration of:

- **Timing**: Initiation after development of hypoxemia (requiring oxygen), not during early viral replication phase
- **Dose**: RECOVERY dose (dexamethasone 6 mg daily) represents moderate-dose therapy; higher doses (methylprednisolone 1-2 mg/kg) used in some protocols but lacking definitive evidence
- **Duration**: Typically 5-10 days, with tapering to avoid adrenal insufficiency
- **Patient selection**: Identification of patients most likely to benefit (those with evidence of hyperinflammation)

6.4.4 Risks and Adverse Effects

Corticosteroid therapy carries potential risks:

- **Delayed viral clearance**: Theoretical concern, though not demonstrated in RECOVERY
- **Secondary infections**: Increased risk of bacterial and fungal superinfections
- **Hyperglycemia**: Exacerbation of stress hyperglycemia; requires monitoring and management
- **Adrenal suppression**: Prolonged therapy may suppress endogenous HPA axis, requiring taper
- **Psychiatric effects**: Mood disturbances, psychosis in susceptible individuals

6.4.5 Corticosteroid Resistance and Response Prediction

Given the heterogeneity of COVID-19 outcomes, identifying predictors of corticosteroid response could enable personalized therapy. Potential biomarkers include:

- **C-reactive protein (CRP)** : Elevated CRP may identify hyperinflammatory phenotype likely to benefit
- **IL-6**: Direct marker of inflammatory activity
- **Ferritin**: Marker of macrophage activation
- **Lymphocyte count**: Severe lymphopenia may indicate excessive immunosuppression risk
- **Cortisol levels**: Low cortisol may identify CIRCI patients requiring replacement

Prospective studies validating biomarker-guided corticosteroid strategies are needed.

7. DIAGNOSTIC APPROACH TO ADRENAL DYSFUNCTION IN COVID-19

7.1 Clinical Suspicion Indices

Given the protean manifestations of adrenal dysfunction, maintaining high index of suspicion is essential. Indications for adrenal assessment in COVID-19 patients include:

7.1.1 During Acute Illness

- **Unexplained hypotension**: Requiring vasopressor support despite adequate fluid resuscitation
- **Electrolyte disturbances**: Hyponatremia, hyperkalemia, or both
- **Hypoglycemia**: Particularly in non-diabetic patients
- **Prolonged fever**: Without identifiable infectious source
- **Failure to improve**: Despite appropriate supportive care
- **Eosinophilia**: Relative eosinophilia in critically ill patient
- **Unexplained metabolic acidosis**: With normal lactate
- **Severe illness**: Particularly those requiring mechanical ventilation or with ARDS

7.1.2 During Recovery and Follow-up

- **Persistent fatigue**: Disproportionate to illness severity
- **Orthostatic symptoms**: Dizziness, lightheadedness on standing
- **Weight loss**: Unexplained despite adequate nutrition
- **Nausea, vomiting, abdominal pain**: Unexplained gastrointestinal symptoms
- **Salt craving**: Particularly in primary adrenal insufficiency
- **Hyperpigmentation**: In primary adrenal insufficiency (delayed manifestation)
- **Autoimmune symptoms**: Suggesting post-viral autoimmune endocrinopathy
- **Long COVID syndrome**: Unexplained persistent symptoms

7.2 Laboratory Assessment

7.2.1 Basal Hormone Measurements

Morning cortisol (collected 8-9 AM):

- **< 3 µg/dL (83 nmol/L)** : Strongly suggests adrenal insufficiency
- **3-15 µg/dL (83-414 nmol/L)** : Indeterminate; requires dynamic testing
- **> 15 µg/dL (414 nmol/L)** : Adrenal insufficiency unlikely

Plasma ACTH (collected simultaneously with cortisol):

- **Elevated (> 2x upper normal)** : Suggests primary adrenal insufficiency
- **Low or inappropriately normal**: Suggests secondary adrenal insufficiency

Aldosterone and renin:

- **Low aldosterone with high renin**: Mineralocorticoid deficiency (primary insufficiency)
- **Normal aldosterone with normal renin**: Mineralocorticoid axis intact (secondary insufficiency)

7.2.2 Dynamic Function Tests

ACTH stimulation test (250 µg) :

- Procedure: Administer 250 μg cosyntropin IV/IM; measure cortisol at 0, 30, and 60 minutes
- Interpretation: Peak cortisol < 18 μg/dL (500 nmol/L) indicates adrenal insufficiency
- Caveats: May miss recent-onset secondary insufficiency (adrenal atrophy takes time); may be normal in partial secondary insufficiency

Low-dose ACTH stimulation test (1 μg) :

- May be more sensitive for secondary insufficiency
- Less standardized; interpret cautiously

CRH stimulation test:

- Distinguishes hypothalamic from pituitary causes of secondary insufficiency
- Limited availability; rarely needed for clinical management

Metyrapone test:

- Assesses entire HPA axis integrity
- Requires specialized monitoring; rarely used in COVID-19 context

7.2.3 Special Considerations in COVID-19

Several factors complicate interpretation of endocrine testing in COVID-19 patients:

- **Critical illness effects**: Elevate cortisol, potentially masking insufficiency
- **Hypoalbuminemia**: Reduces total cortisol; free cortisol measurement may be more accurate
- **Cytokine effects**: May cause ACTH-cortisol dissociation
- **Medication effects**: Exogenous corticosteroids (including dexamethasone) suppress HPA axis and interfere with testing
- **Timing**: Testing during acute illness may reflect transient dysfunction; repeat testing after recovery may be needed

7.3 Imaging Studies

7.3.1 Adrenal Imaging

CT abdomen:

- Indications: Suspected primary adrenal insufficiency, unexplained abdominal pain, adrenal hemorrhage risk
- Findings: Enlargement (acute hemorrhage/infarction), atrophy (chronic insufficiency), masses, calcifications
- Advantages: Widely available; can assess other abdominal organs
- Limitations: Radiation exposure; may miss subtle abnormalities

MRI abdomen:

- Superior for characterizing adrenal masses and hemorrhage
- May detect adrenal signal abnormalities in COVID-19 patients without overt hemorrhage

7.3.2 Pituitary Imaging

MRI pituitary with contrast:

- Indications: Suspected secondary adrenal insufficiency, particularly if other pituitary hormone deficiencies present
- Findings: Enlargement (hypophysitis), empty sella, apoplexy (hemorrhage/infarction)
- Advantages: Excellent soft tissue detail
- Limitations: Availability; cost; may be normal in functional HPA suppression

7.4 Screening Recommendations

Based on current evidence, we propose the following screening approach:

7.4.1 During Hospitalization

- **All patients with severe COVID-19**: Consider morning cortisol and electrolytes
- **Patients with hypotension/shock**: Low threshold for ACTH stimulation testing
- **Patients with unexplained electrolyte abnormalities**: Assess adrenal axis
- **Patients receiving corticosteroids**: Document indication and duration; plan for HPA axis assessment after withdrawal

7.4.2 Post-Discharge Follow-up

- **Patients with severe COVID-19**: Consider endocrine referral and HPA axis assessment at 3-6 months post-recovery
- **Patients with persistent symptoms**: Low threshold for endocrine evaluation
- **Patients with documented adrenal dysfunction during acute illness**: Repeat testing to assess recovery
- **Patients who received prolonged corticosteroids**: Assess HPA axis after steroid withdrawal

7.5 Long-Term Monitoring

For patients with documented adrenal insufficiency:

- **Regular clinical assessment**: Every 3-6 months initially, then annually if stable
- **Repeat biochemical testing**: At 6-12 months to assess recovery in patients with transient insufficiency
- **Medication adjustment**: Based on clinical status, weight changes, intercurrent illness
- **Patient education**: Reinforce sick day rules, emergency preparedness
- **Monitoring for associated conditions**: Particularly in autoimmune-mediated insufficiency

8. THERAPEUTIC APPROACHES AND MANAGEMENT STRATEGIES

8.1 Corticosteroid Therapy in Acute COVID-19

8.1.1 Indications

Based on current guidelines (NIH COVID-19 Treatment Guidelines, WHO Living Guidelines), corticosteroid therapy is indicated for:

- **Hospitalized patients requiring supplemental oxygen**: Dexamethasone 6 mg daily for up to 10 days
- **Patients requiring mechanical ventilation or ECMO**: Dexamethasone 6 mg daily for up to 10 days
- **Patients with refractory shock**: Consider hydrocortisone 200 mg/day if vasopressor-dependent

Corticosteroids are not routinely recommended for patients not requiring oxygen support.

8.1.2 Dosing Regimens

Dexamethasone:

- Standard dose: 6 mg once daily (oral or IV)
- Duration: Up to 10 days or until hospital discharge

Hydrocortisone (alternative):

- 50 mg IV every 6 hours or 200 mg continuous infusion
- Particularly if mineralocorticoid activity desired or rapid titration needed

Methylprednisolone:

- Alternative at equivalent anti-inflammatory doses (32 mg methylprednisolone ≈ 6 mg dexamethasone)
- Some protocols use higher "pulse" doses (250-1000 mg) for severe ARDS, though evidence lacking

8.1.3 Monitoring During Therapy

Patients receiving corticosteroids require monitoring for:

- **Glycemic control**: Frequent blood glucose monitoring; insulin therapy as needed
- **Infectious complications**: Vigilance for secondary bacterial or fungal infections
- **Electrolyte abnormalities**: Particularly with hydrocortisone (mineralocorticoid effects)
- **Adrenal suppression**: Plan for taper after prolonged therapy

8.2 Management of Adrenal Insufficiency

8.2.1 Acute Adrenal Crisis

Adrenal crisis is a medical emergency requiring immediate treatment:

- **Immediate actions**:
  - Hydrocortisone 100 mg IV bolus, then 200 mg/24 hours continuous infusion or 50 mg IV q6h
  - Rapid IV fluid resuscitation (0.9% saline or 5% dextrose in saline)
  - Correct hypoglycemia (if present)
  - Identify and treat precipitating cause
- **Subsequent management**:
  - Transition to oral replacement when clinically stable
  - Mineralocorticoid replacement (fludrocortisone) if primary insufficiency and receiving hydrocortisone < 50 mg/day
  - Patient education regarding prevention of future crises

8.2.2 Chronic Replacement Therapy

Glucocorticoid replacement:

- Hydrocortisone: 15-25 mg/day in divided doses (typically 10 mg on awakening, 5 mg at midday, 5 mg late afternoon)
- Prednisolone: 3-5 mg once daily (alternative, particularly if adherence concerns)
- Dose titration based on clinical response (energy levels, weight, blood pressure), not hormone levels

Mineralocorticoid replacement (primary insufficiency only):

- Fludrocortisone: 0.05-0.2 mg once daily
- Monitor electrolytes, blood pressure, and renin for dose adjustment

8.2.3 Stress Dosing

Patients with adrenal insufficiency require increased glucocorticoid doses during intercurrent illness, injury, or procedures:

- **Minor illness (febrile, ambulatory)** : Double or triple usual dose for 2-3 days
- **Moderate illness (requiring bed rest)** : 50 mg hydrocortisone every 8-12 hours
- **Major stress (surgery, trauma, critical illness)** : 100 mg hydrocortisone IV bolus, then 200 mg/day continuous infusion
- **Dental procedures**: Additional 5-10 mg hydrocortisone before procedure

8.2.4 Patient Education

Essential components of patient education include:

- **Sick day rules**: Written instructions for dose adjustment during illness
- **Emergency kit**: Injectable hydrocortisone for emergency use
- **Medical alert identification**: Bracelet, necklace, or wallet card
- **Travel advice**: Carrying extra medication, understanding time zone adjustments
- **When to seek help**: Symptoms of adrenal crisis requiring emergency care

8.3 Management of Glucocorticoid Resistance

No specific therapies target glucocorticoid resistance directly, but several strategies may be considered:

8.3.1 Dose Optimization

- **Higher initial doses**: May be required to overcome resistance in acute inflammation
- **Individualized dosing**: Based on clinical response rather than fixed protocols
- **Alternative corticosteroids**: Different agents may have varying receptor affinities and resistance profiles

8.3.2 Combination with Other Agents

- **IL-6 inhibitors**: Tocilizumab may reduce cytokine-mediated GR resistance by lowering IL-6 levels
- **JAK inhibitors**: Baricitinib and other JAK inhibitors may modulate inflammatory signaling pathways affecting GR function
- **NF-κB inhibitors**: Experimental agents targeting NF-κB could reduce competition for GR

8.3.3 GR-Targeted Approaches

- **Selective glucocorticoid receptor modulators (SEGRMs)** : Agents with dissociated properties (transrepression without transactivation) may have improved therapeutic index
- **GR-α/GR-β modulation**: Experimental strategies to reduce GR-β expression or enhance GR-α activity

8.4 Post-COVID Follow-up and Rehabilitation

8.4.1 Endocrine Follow-up

Patients with documented adrenal dysfunction during acute illness should receive:

- **Endocrine consultation**: Within 1-3 months of hospital discharge
- **Repeat biochemical testing**: At 3-6 months to assess recovery

- **Medication adjustment**: As indicated by clinical and biochemical status
- **Long-term monitoring**: For patients with permanent insufficiency

8.4.2 Multidisciplinary Approach

Given the multisystem nature of COVID-19 sequelae, comprehensive follow-up may involve:

- **Endocrinology**: HPA axis assessment, other endocrine axes
- **Pulmonology**: Lung function assessment, rehabilitation
- **Cardiology**: Cardiovascular evaluation
- **Neurology**: Cognitive assessment, autonomic function testing
- **Rehabilitation medicine**: Physical and occupational therapy
- **Mental health**: Psychological support for post-ICU syndrome

8.4.3 Patient Support and Education

- **Information resources**: Reliable information about COVID-19 sequelae
- **Support groups**: Connecting with other long COVID patients
- **Symptom tracking**: Diaries to monitor progress and identify patterns
- **Graded exercise**: Structured return to physical activity

9. FUTURE DIRECTIONS AND RESEARCH PRIORITIES

9.1 Knowledge Gaps

Despite substantial progress, significant knowledge gaps remain regarding SARS-CoV-2 effects on adrenal function:

9.1.1 Mechanistic Questions

- **Viral persistence**: Does SARS-CoV-2 establish persistent infection in adrenal tissue, contributing to long-term dysfunction?
- **Autoimmune mechanisms**: What is the role of post-viral autoimmunity in adrenal dysfunction?
- **Genetic susceptibility**: Do genetic variants in ACE2, TMPRSS2, or GR genes influence susceptibility to adrenal involvement?
- **Sex differences**: Are there sex-specific differences in adrenal responses to COVID-19?

9.1.2 Epidemiological Questions

- **True prevalence**: What is the true prevalence of adrenal dysfunction across the spectrum of COVID-19 severity?
- **Risk factors**: Which patients are at highest risk for adrenal involvement?
- **Natural history**: What is the long-term trajectory of adrenal dysfunction in recovered patients?
- **Vaccination effects**: Does vaccination alter risk of adrenal involvement in breakthrough infections?

9.1.3 Diagnostic Questions

- **Optimal testing**: What is the most accurate and practical approach to diagnosing adrenal dysfunction in COVID-19 patients?
- **Biomarkers**: Can biomarkers predict which patients will develop adrenal insufficiency?
- **Imaging role**: What is the role of adrenal imaging in COVID-19 patients?

9.1.4 Therapeutic Questions

- **Corticosteroid optimization**: What is the optimal dose, duration, and timing of corticosteroid therapy?
- **Adjunctive therapies**: Do other immunomodulators enhance or reduce corticosteroid efficacy?
- **Rehabilitation strategies**: What interventions improve recovery in patients with post-COVID adrenal dysfunction?

9.2 Priority Research Directions

Based on identified knowledge gaps, priority research directions include:

9.2.1 Prospective Cohort Studies

Large, multicenter prospective cohort studies with:

- Systematic endocrine evaluation at multiple time points (acute illness, 3, 6, 12, 24 months)
- Comprehensive phenotyping (clinical, biochemical, imaging)
- Biobanking for mechanistic studies
- Long-term follow-up to determine natural history

9.2.2 Mechanistic Studies

Laboratory investigations addressing:

- SARS-CoV-2 infection of adrenal cells in vitro and in vivo
- Effects of viral proteins on steroidogenesis and GR signaling
- Role of specific cytokines in adrenal dysfunction
- Autoantibody development following infection

9.2.3 Clinical Trials

Randomized controlled trials evaluating:

- Alternative corticosteroid regimens (different agents, doses, durations)
- Adjunctive therapies targeting specific mechanisms (IL-6 inhibition, JAK inhibition)
- Rehabilitation interventions for patients with persistent symptoms

9.2.4 Translational Studies

Studies bridging basic and clinical research:

- Development and validation of diagnostic algorithms
- Identification and validation of prognostic biomarkers
- Personalized medicine approaches to corticosteroid therapy

9.3 Emerging Therapeutic Targets

Advances in understanding COVID-19-associated adrenal dysfunction may identify novel therapeutic targets:

9.3.1 GR-Targeted Therapies

- **GR-α upregulators**: Strategies to increase GR-α expression in target tissues
- **GR-β inhibitors**: Agents that reduce GR-β expression or block its dominant-negative effects
- **Selective GR modulators**: Compounds with improved therapeutic index

9.3.2 Anti-Cytokine Therapies

- **IL-6 inhibitors**: Already in use; may have dual benefits (reducing inflammation and improving GR sensitivity)
- **IL-1 inhibitors**: Anakinra and other agents targeting IL-1 pathway
- **TNF-α inhibitors**: Potential role in selected patients

9.3.3 Metabolic Modulators

- **11β-HSD1 inhibitors**: Modulate tissue-specific cortisol availability
- **GR chaperone modulators**: Agents affecting GR folding and trafficking

9.3.4 Regenerative Approaches

- **Stem cell therapy**: Potential for adrenal regeneration in permanent insufficiency
- **Gene therapy**: For genetic forms of adrenal insufficiency

9.4 International Collaboration

Given the global nature of the COVID-19 pandemic, international collaboration is essential:

- **Data sharing**: Pooling data across centers and countries
- **Standardized protocols**: Harmonizing diagnostic and therapeutic approaches
- **Biobank networks**: Sharing samples for mechanistic studies
- **Clinical trial networks**: Coordinating multicenter trials

10. CONCLUSIONS

10.1 Summary of Key Findings

This comprehensive review has synthesized current knowledge regarding SARS-CoV-2 effects on cortisol secretion, glucocorticoid receptor function, and HPA axis integrity. Key findings include:

1. **SARS-CoV-2 exhibits significant tropism for adrenal tissue**, mediated by ACE2 and TMPRSS2 expression in adrenocortical cells, particularly in zona fasciculata and zona reticularis.
2. **Multiple pathogenetic mechanisms contribute to adrenal dysfunction**:
    - Direct cytopathic effects with vasculitis, thrombosis, and adrenal hemorrhage or infarction
    - Secondary adrenal insufficiency due to central HPA axis dysfunction from hypothalamic or pituitary viral invasion
    - Immune-mediated inflammation with cytokine storm disrupting normal feedback regulation
    - Molecular mimicry between viral sequences and ACTH potentially generating cross-reactive immune responses
    - Dissociation between ACTH and cortisol regulation in critical illness
3. **Glucocorticoid receptor alterations**—including reduced GR-α expression, increased GR-β expression, and impaired post-receptor signaling—contribute to tissue glucocorticoid resistance, compounding the effects of altered cortisol secretion.
4. **Critical illness-related corticosteroid insufficiency (CIRCI)** is common in severe COVID-19, characterized by inadequate cellular corticosteroid activity for illness severity and associated with worse outcomes.
5. **Transient central hypocortisolism** has been documented in recovered patients, resolving within one year in approximately two-thirds of cases, though a subset may develop permanent adrenal insufficiency.
6. **The complex bidirectional relationship between cortisol and the immune system** is dysregulated in COVID-19, contributing to cytokine storm, lymphopenia, and altered Th1/Th2 balance.
7. **Corticosteroid therapy** (dexamethasone 6 mg daily) reduces mortality in severely ill COVID-19 patients requiring respiratory support, likely through multiple mechanisms including inflammation suppression and correction of CIRCI.

10.2 Clinical Implications

These findings have important implications for clinical practice:

1. **Maintain high index of suspicion** for adrenal dysfunction in COVID-19 patients, particularly those with unexplained hypotension, electrolyte disturbances, or prolonged recovery.
2. **Low threshold for diagnostic testing** in at-risk patients, using appropriate combinations of basal hormones and dynamic function tests.
3. **Recognize CIRCI as a treatable condition** in critically ill patients, with corticosteroid replacement potentially improving outcomes.
4. **Individualize corticosteroid therapy** based on disease severity, timing, and patient characteristics, balancing benefits against risks.
5. **Provide long-term follow-up** for recovered patients, including endocrine assessment at 3-6 months post-recovery.
6. **Educate patients** with documented adrenal insufficiency regarding sick day rules, emergency preparedness, and when to seek medical attention.

10.3 Unanswered Questions

Despite substantial progress, many questions remain:

- What is the true prevalence of permanent adrenal insufficiency following COVID-19?
- Can we predict which patients will recover and which will develop permanent dysfunction?
- What is the optimal approach to diagnosing adrenal dysfunction in the context of critical illness and its sequelae?
- How should we monitor and manage patients with subclinical HPA axis abnormalities?
- What are the long-term consequences of COVID-19-associated adrenal dysfunction for overall health and quality of life?

10.4 Final Remarks

The COVID-19 pandemic has provided unprecedented opportunity to study viral-endocrine interactions, revealing the profound vulnerability of the HPA axis to SARS-CoV-2 infection. The resulting insights into adrenal pathophysiology extend beyond COVID-19, informing our understanding of

viral endocrinology more broadly and potentially guiding management of other viral illnesses affecting the endocrine system.

For clinicians caring for COVID-19 patients, awareness of potential adrenal dysfunction is essential for optimal management during acute illness and appropriate follow-up after recovery. For researchers, the many remaining questions provide a rich agenda for future investigation. For patients, understanding the endocrine consequences of COVID-19 offers hope for appropriate diagnosis and treatment of persistent symptoms that might otherwise remain unexplained.

As we continue to grapple with the acute and long-term consequences of the COVID-19 pandemic, attention to the endocrine system—and particularly the adrenal glands—will remain essential for comprehensive patient care. The lessons learned will undoubtedly inform our approach to other viral illnesses and may ultimately improve outcomes for patients with diverse endocrine disorders.

REFERENCES

Abdel-Moneim, A., & Hosni, A. (2021). Insights into the possible impact of COVID-19 on the endocrine system. *Archives of Physiology and Biochemistry*, 129(4), 998-1006.

Alzahrani, A. S., Mukhtar, N., Aljomaiah, A., Aljamei, H., Bakhsh, A., Alsudani, N., ... & Sulaiman, O. (2020). The impact of COVID-19 viral infection on the hypothalamic-pituitary-adrenal axis. *Endocrine Practice*, 27(2), 83-89.

Annane, D., Pastores, S. M., Arlt, W., Balk, R. A., Beishuizen, A., Briegel, J., ... & Van den Berghe, G. (2017). Critical illness-related corticosteroid insufficiency (CIRCI): A narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). *Intensive Care Medicine*, 43(12), 1781-1792.

Bamberger, C. M., Schulte, H. M., & Chrousos, G. P. (1996). Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. *Endocrine Reviews*, 17(3), 245-261.

de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016). SARS and MERS: Recent insights into emerging coronaviruses. *Nature Reviews Microbiology*, 14(8), 523-534.

DeSantis, A. S., DiezRoux, A. V., Hajat, A., Aiello, A. E., Golden, S. H., Jenny, N. S., ... & Shea, S. (2012). Associations of salivary cortisol levels with inflammatory markers: The multi-ethnic study of atherosclerosis. *Psychoneuroendocrinology*, 37(7), 1009-1018.

Fara, S., Allora, A., Castellino, L., di Filippo, L., Loli, P., & Giustina, A. (2021). COVID-19 and the pituitary. *Pituitary*, 24(3), 465-481.

Ferrau, F., Ceccato, F., Cannavo, S., & Scaroni, C. (2021). What we have to know about corticosteroids use during SARS-CoV-2 infection. *Journal of Endocrinological Investigation*, 44(4), 693-701.

Fox, B. (1976). Venous infarction of the adrenal glands. *Journal of Pathology*, 119(2), 65-89.

Gil-Etayo, F. J., Suárez-Fernández, P., Cabrera-Marante, O., Arroyo, D., Garcinuño, S., Naranjo, L., ... & Serrano, A. (2021). T-helper cell subset response is a determining factor in COVID-19 progression. *Frontiers in Cellular and Infection Microbiology*, 11, 624483.

Glaser, R., & Kiecolt-Glaser, J. K. (2005). Stress-induced immune dysfunction: Implications for health. *Nature Reviews Immunology*, 5(3), 243-251.

Gu, J., & Korteweg, C. (2007). Pathology and pathogenesis of severe acute respiratory syndrome. *American Journal of Pathology*, 170(4), 1136-1147.

Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., ... & Landry, D. W. (2020). Extrapulmonary manifestations of COVID-19. *Nature Medicine*, 26(7), 1017-1032.

Hakan, T., Sarı, R., & Toprak, İ. D. (2021). Critical illness-related corticosteroid insufficiency is common in Covid-19 and treatment provide survival benefit. *Research Square*. https://doi.org/10.21203/rs.3.rs-391924/v1

Hänsel, A., Hong, S., Cámara, R. J., & von Känel, R. (2010). Inflammation as a psychophysiological biomarker in chronic psychosocial stress. *Neuroscience and Biobehavioral Reviews*, 35(1), 115-121.

Hashim, M., Athar, S., & Gaba, W. H. (2021). New onset adrenal insufficiency in a patient with COVID-19. *BMJ Case Reports*, 14(1), e237690.

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., ... & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*, 181(2), 271-280.

Hosseini, P., Fallahi, M. S., Erabi, G., Pakdin, M., Zarezadeh, S. M., Faridzadeh, A., ... & Deravi, N. (2022). Multisystem inflammatory syndrome and autoimmune diseases following COVID-19: Molecular mechanisms and therapeutic opportunities. *Frontiers in Molecular Biosciences*, 9, 804109.

Ilias, I., Vassiliou, A. G., Keskinidou, C., Vrettou, C. S., Orfanos, S., Kotanidou, A., & Dimopoulou, I. (2023). Changes in cortisol secretion and corticosteroid receptors in COVID-19 and non COVID-19 critically ill patients with sepsis/septic shock and scope for treatment. *Biomedicines*, 11(7), 1801.

Jensterle, M., Herman, R., Janez, A., Mahmeed, A., Al-Rasadi, K., Al-Alawi, K., ... & Rizzo, M. (2022). The relationship between COVID-19 and hypothalamic-pituitary-adrenal axis: A large spectrum from glucocorticoid insufficiency to excess—The CAPISCO international expert panel. *International Journal of Molecular Sciences*, 23(13), 7326.

Kanczkowski, W., Gaba, W. H., Krone, N., Varga, Z., Beuschlein, F., Hantel, C., ... & Bornstein, S. R. (2022). Adrenal gland function and dysfunction during COVID-19. *Hormone and Metabolic Research*, 54(8), 532-539.

Katz, A., Altshuler, D., Papadopoulos, J., Amoroso, N., Goldenberg, R., Tarras, E., ... & Brosnahan, S. B. (2022). The use of high-dose corticosteroids versus low-dose corticosteroids with and without tocilizumab in COVID-19 acute respiratory distress syndrome. *The Annals of Pharmacotherapy*, 57(1), 5-15.

Kunz-Ebrecht, R., Mohamed-Ali, V., Feldman, J., Kirschbaum, C., & Steptoe, A. (2003). Cortisol responses to mild psychological stress are inversely associated with proinflammatory cytokines. *Brain, Behavior, and Immunity*, 17(5), 373-383.

Leow, M. K., Kwek, D. S., Ng, A. W., Ong, K. C., Kaw, G. J., & Lee, L. S. (2005). Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). *Clinical Endocrinology*, 63(2), 197-202.

Leyendecker, P., Ritter, S., Riou, M., Wackenthaler, A., Meziani, F., Roy, C., & Ohana, M. (2020). Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-CoV-2 infection: A retrospective cohort analysis on 219 patients. *European Radiology*, 31(2), 895-900.

Li, M. Y., Li, L., Zhang, Y., & Wang, X. S. (2020). Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infectious Diseases of Poverty*, 9(1), 45.

Mao, Y., Xu, B., Guan, W., Xu, D., Li, F., Ren, R., ... & Jiang, L. (2020). The adrenal cortex, an underestimated site of SARS-CoV-2 infection. *Frontiers in Endocrinology*, 11, 593179.

Miller, W. L., & Auchus, R. J. (2019). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocrine Reviews*, 40(4), 1023-1062.

Müller, J. A., Groß, R., Conzelmann, C., Krüger, J., Merle, U., Steinhart, J., ... & Heller, S. (2021). SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. *Nature Metabolism*, 3(2), 149-165.

Oguz, S. H., & Yildiz, B. O. (2023). Endocrine disorders and COVID-19. *Annual Review of Medicine*, 74, 75-88.

Pal, R. (2022). COVID-19 and hypothalamic-pituitary-adrenal axis: A narrative review. *Hormones*, 21(2), 211-219.

Pal, R., & Banerjee, M. (2020). COVID-19 and the endocrine system: Exploring the unexplored. *Journal of Endocrinological Investigation*, 43(7), 1027-1031.

RECOVERY Collaborative Group. (2021). Dexamethasone in hospitalized patients with Covid-19. *New England Journal of Medicine*, 384(8), 693-704.

Rotondi, M., Coperchini, F., Ricci, G., Denegri, M., Croce, L., Ngnitejeu, S. T., ... & Chiovato, L. (2021). Detection of SARS-CoV-2 receptor ACE2 in human follicular cells: A key to the thyroid tropism of the virus. *Journal of Endocrinological Investigation*, 44(9), 1917-1924.

Savla, S. R., Prabhavalkar, K. S., & Bhatt, L. K. (2021). Cytokine storm associated with severe COVID-19: A comprehensive review. *Inflammopharmacology*, 29(3), 683-698.

Sharrack, N., Baxter, C. T., Paddock, M., & Uchegbu, E. (2020). Adrenal haemorrhage as a complication of COVID-19 infection. *BMJ Case Reports*, 13(11), e238643.

Sher, E. K., Ćosović, A., Džidić-Krivić, A., & Banjari, I. (2023). COVID-19 and immune dysfunction: A comprehensive review of mechanisms and implications. *International Journal of Molecular Sciences*, 24(3), 2345.

Smith, S. M., & Vale, W. W. (2022). The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. *Dialogues in Clinical Neuroscience*, 8(4), 383-395.

Stefunkova, M., Calkovska, A., & Calkovsky, V. (2021). Expression of ACE2 and TMPRSS2 in the adrenal gland: A potential target for SARS-CoV-2 infection. *Endocrine Regulations*, 55(3), 156-162.

Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., ... & HCA Lung Biological Network. (2020). SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nature Medicine*, 26(5), 681-687.

Vakhshoori, M., Heidarpour, M., & Shafie, D. (2021). Adrenal insufficiency in coronavirus disease 2019: A case report and review of the literature. *Journal of Research in Medical Sciences*, 26, 45.

Vassiliadi, D. A., Dimopoulou, I., & Tsagarakis, S. (2021). The role of the hypothalamic-pituitary-adrenal axis in the pathophysiology and management of sepsis. *Current Opinion in Critical Care*, 27(4), 393-399.

Wang, Z., & Xu, X. (2020). scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, Leydig and Sertoli cells. *Cells*, 9(4), 920.

Wepler, M., Rehm, M., & Thiel, M. (2020). The role of the hypothalamic-pituitary-adrenal axis in sepsis. *Anesthesia & Analgesia*, 131(2), 421-433.

WHO REACT Working Group. (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. *JAMA*, 324(13), 1330-1341.

Wolkow, A., Aisbett, B., Reynolds, J., Ferguson, S. A., & Main, L. C. (2015). Relationships between inflammatory cytokine and cortisol responses in firefighters exposed to simulated wildfire suppression. *Applied Ergonomics*, 48, 42-49.

Wong, R. S. Y., Chee, K. H., & Chong, E. T. J. (2021). The endocrine system in COVID-19: A review of current evidence. *Endocrine Connections*, 10(3), R77-R90.